Type 2 diabetes and metabolism studies

  

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 Years of Age

Investigator:

T Barrett t.g.barrett@bham.ac.uk

Sponsor:

Astra Zeneca

Summary:

The purpose of this research study is to evaluate the effectiveness and safety of dapagliflozin and saxagliptin in patients with Type 2 Diabetes who are aged 10 to below 18 years old and are currently taking metformin, insulin, or both medicines.

Start Date:

End Date:

Further Information: